mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!

Author:

Chavda Vivek P.1ORCID,Jogi Gargi1,Dave Srusti2,Patel Bhoomika M.3ORCID,Vineela Nalla Lakshmi4,Koradia Krishna5

Affiliation:

1. Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380009, India

2. Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad 382481, India

3. School of Medico-legal Studies, National Forensic Sciences University, Gandhinagar 382007, India

4. Department of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram 522302, India

5. Department of Pharmaceutics, Saurashtra University, Rajkot 360005, India

Abstract

mRNA vaccines take advantage of the mechanism that our cells use to produce proteins. Our cells produce proteins based on the knowledge contained in our DNA; each gene encodes a unique protein. The genetic information is essential, but cells cannot use it until mRNA molecules convert it into instructions for producing specific proteins. mRNA vaccinations provide ready-to-use mRNA instructions for constructing a specific protein. BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) both are newly approved mRNA-based COVID-19 vaccines that have shown excellent protection and efficacy. In total, there are five more mRNA-based vaccine candidates for COVID-19 under different phases of clinical development. This review is specifically focused on mRNA-based vaccines for COVID-19 covering its development, mechanism, and clinical aspects.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference118 articles.

1. WHO (2023, January 17). WHO Coronavirus (COVID-19) Dashboard 2023, Available online: https://covid19.who.int/.

2. COVID-19 Pandemic in India: Present Scenario and a Steep Climb Ahead;Pal;J. Prim. Care Community Health,2020

3. COVID-19: Emergence, Spread, Possible Treatments, and Global Burden;Keni;Front. Public Health,2020

4. Chavda, V.P., Ping, F.-F., and Chen, Z.-S. (2022). An Impact of COVID-19 on Cancer Care: An Update. Vaccines, 10.

5. Coronavirus Disease 2019 (COVID-19): A Literature Review;Harapan;J. Infect. Public Health,2020

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3